Law Offices of Thomas J. Lamb

  • Free Case Evaluation
  • Mesothelioma & Asbestos Diseases
  • Legal Compensation
  • Asbestos Overview
  • Common Questions
  • About Our Firm

Surgery for malignant pleural mesothelioma after radiotherapy (SMART): final results from a single-centre, phase 2 trial

January 14, 2021 By Thomas Lamb

Background:  A novel approach for managing malignant pleural mesothelioma, surgery for mesothelioma after radiotherapy (SMART), consisting of a short accelerated course of high-dose, hemithoracic, intensity modulated radiotherapy (IMRT) followed by extrapleural pneumonectomy was developed. The aim of this study was to evaluate the clinical … [Read more...]

Filed Under: Medicine, Mesothelioma Tagged With: chemotherapy, extrapleural pneumonectomy, malignant pleural mesothelioma (MPM), mesothelioma, mesothelioma treatments, Radiotherapy

Talc-Based Beauty Products Found to be Contaminated With Asbestos

December 14, 2020 By Thomas Lamb

For years, cosmetics and personal care products have included a mineral ingredient called talc in their manufacturing process. Talc's original intention was to improve the texture and feel of products, absorb moisture, or simply be a filler ingredient. However, due to the mining process of the mineral, talc has been found to be contaminated with … [Read more...]

Filed Under: Asbestos, Asbestosis, Mesothelioma, Talc, Uncategorized Tagged With: asbestos, asbestos exposure, asbestos talc lawsuits, asbestos-infused talc, talcum powder mesothelioma lawsuits, talcum powder products

Chemo-Free Regimen Boosts OS in Mesothelioma

November 23, 2020 By Thomas Lamb

A chemotherapy-free combination significantly improved overall survival (OS) as initial therapy for unresectable malignant pleural mesothelioma (MPM), a large randomized trial showed. Patients treated with nivolumab (Opdivo) and ipilimumab (Yervoy) had a media OS of 18.1 months versus 14.1 months for patients randomized to chemotherapy. The … [Read more...]

Filed Under: Medicine, Mesothelioma Tagged With: malignant pleural mesothelioma (MPM), mesothelioma, mesothelioma treatments

Dying Patients Denied Justice Amid COVID-Related Court Delays

November 13, 2020 By Thomas Lamb

Terminally ill plaintiffs, who were supposed to be guaranteed expedited trials in light of their deteriorating medical conditions, are still waiting for their day in court, according to an NBC Bay Area investigation. [ Terminally ill plaintiffs ] who are dying are supposed to be granted preferential treatment when it comes to scheduling their … [Read more...]

Filed Under: Law, Lawsuits, Mesothelioma Tagged With: mesothelioma, mesothelioma lawsuits

Mesothelioma risk among those exposed to chrysotile asbestos only and mixtures that include amphibole: a case–control study in the USA, 1975–1980

November 5, 2020 By Thomas Lamb

Objectives Occupational asbestos exposure is causally linked to mesothelioma. However, whether exposure to only chrysotile asbestos is associated with mesothelioma risk, and the heterogeneity in risk by different fibre types/lengths remains unclear. We investigated whether mesothelioma risk differs among workers exposed to only chrysotile … [Read more...]

Filed Under: Asbestos, Exposure, Mesothelioma Tagged With: asbestos, asbestos exposure, asbestos fibers, mesothelioma

Biomarker candidates could aid in earlier diagnosis of mesothelioma

October 22, 2020 By Thomas Lamb

Mesothelioma is a deadly cancer mainly caused by exposure to asbestos fibers. Unfortunately, mesothelioma is generally diagnosed at an already advanced stage and none of the therapeutic strategies tried so far is able to eradicate the disease. So new biomarkers that could help to identify the disease at an earlier stage are urgently … [Read more...]

Filed Under: Medicine, Mesothelioma Tagged With: asbestos, asbestos exposure, mesothelioma, mesothelioma diagnosis

A multicentre randomised phase III trial comparing pembrolizumab vs single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial

October 16, 2020 By Thomas Lamb

Background:  Malignant pleural mesothelioma (MPM) is an aggressive malignancy characterized by limited treatment options and a poor prognosis. At relapse after platinum-based chemotherapy, single-agent chemotherapy is commonly used and single-arm trials of immune-checkpoint inhibitors have demonstrated encouraging activity. Patients and … [Read more...]

Filed Under: Medicine, Mesothelioma Tagged With: malignant pleural mesothelioma (MPM), mesothelioma, mesothelioma treatments

FDA Approves Drug Combination for Treating Mesothelioma

October 12, 2020 By Thomas Lamb

[On October 02, 2020], the U.S. Food and Drug Administration approved Opdivo (nivolumab) in combination with Yervoy (ipilimumab) for the first-line treatment of adults with malignant pleural mesothelioma that cannot be removed by surgery. This is the first drug regimen approved for mesothelioma in 16 years and the second FDA-approved systemic … [Read more...]

Filed Under: Medicine, Mesothelioma Tagged With: malignant pleural mesothelioma (MPM), mesothelioma, mesothelioma treatments

Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in

October 2, 2020 By Thomas Lamb

Background:  There is a strong unmet need to improve systemic therapy in mesothelioma. Chemotherapy with cisplatin and pemetrexed improves survival in malignant pleural mesothelioma, and immune checkpoint inhibitors are an emerging treatment in this disease. We aimed to evaluate the activity of durvalumab, an anti-PD-L1 antibody, given during … [Read more...]

Filed Under: Medicine, Mesothelioma Tagged With: chemotherapy, cisplatin, malignant mesothelioma, malignant pleural mesothelioma (MPM), mesothelioma, mesothelioma treatments, pemetrexed

FDA clears IND application for CAR T-cell therapy for advanced mesothelioma

September 22, 2020 By Thomas Lamb

The FDA cleared an investigational new drug application for ATA2271, a chimeric antigen receptor T-cell therapy [ or CAR T-cell therapy ] for the treatment of advanced mesothelioma, according to the agent’s manufacturer [which is working together with Memorial Sloan Kettering Cancer Center]. ATA2271 (Atara Biotherapeutics) is an autologous CAR … [Read more...]

Filed Under: Medicine, Mesothelioma Tagged With: mesothelioma, mesothelioma treatments

Next Page »

Do I Have A Possible Case?

If you have a possible asbestos disease or mesothelioma lawsuit, you can get a free, confidential, and no obligation case review from asbestos lawyer Tom Lamb.

Main Navigation Menu

  • Who Was Exposed to Asbestos
  • NC Asbestos Exposure Sites
  • Asbestos-Contaminated Talc
  • Asbestos Diseases
  • Legal Compensation
  • Free Case Evaluation
  • Frequently Asked Questions
  • About Our Law Firm
  • Attorney Tom Lamb
  • Collection of Articles
  • Sitemap

Attorney Tom Lamb

TJL@LambLawOffice.com

Phone: 800-426-9535

Lumina Station, Suite 225
1908 Eastwood Road
Wilmington, North Carolina

Please know that you can use our Quick Contact Form to tell us about your case.

Lamb Law Office Newsletter

Lamb Law Office Newsletter provides periodic updates about some of the cases that we are working on for clients, as well as an information resource you might find helpful.

Subscribe using Form below.

Subscription Form

* indicates required

Our Other Website

Lamb Law Office

Contact Information

Law Offices of Thomas J. Lamb, P.A.
1908 Eastwood Road, Suite 225
Wilmington, North Carolina 28403
910-256-2971 | 800-426-9535
TJL@LambLawOffice.com

  • Home
  • Disclaimer and Copyright Notices
  • Sitemap

Copyright © 2021 · Law Offices of Thomas J. Lamb, P.A.